These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36648561)

  • 21. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
    Pukoli D; Vécsei L
    Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases.
    Oksbjerg NR; Nielsen SD; Blinkenberg M; Magyari M; Sellebjerg F
    Mult Scler Relat Disord; 2021 Jul; 52():102988. PubMed ID: 33979772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients.
    Prockl V; Nickel FT; Utz KS; Fröhlich K; Engelhorn T; Hilz MJ; Lee DH; Linker RA; Huhn K
    J Neurol Sci; 2020 Aug; 415():116973. PubMed ID: 32563101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
    Sorensen PS; Blinkenberg M
    Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.
    Torres JB; Roodselaar J; Sealey M; Ziehn M; Bigaud M; Kneuer R; Leppert D; Weckbecker G; Cornelissen B; Anthony DC
    Front Immunol; 2022; 13():814064. PubMed ID: 35967378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Kira JI; Nakahara J; Sazonov DV; Kurosawa T; Tsumiyama I; Willi R; Zalesak M; Pingili R; Häring DA; Ramanathan K; Kieseier BC; Merschhemke M; Su W; Saida T
    Mult Scler; 2022 Jul; 28(8):1229-1238. PubMed ID: 34787005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Zivadinov R
    Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
    Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
    J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
    [No Abstract]   [Full Text] [Related]  

  • 30. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
    Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
    BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocrelizumab: its efficacy and safety in multiple sclerosis.
    Juanatey A; Blanco-Garcia L; Tellez N
    Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
    Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B
    Mult Scler Relat Disord; 2023 Jan; 69():104459. PubMed ID: 36565573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.
    Gibiansky E; Petry C; Mercier F; Günther A; Herman A; Kappos L; Hauser S; Yamamoto Y; Wang Q; Model F; Kletzl H
    Br J Clin Pharmacol; 2021 Jun; 87(6):2511-2520. PubMed ID: 33202059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis.
    Asha MZI; Al-Asaad Y; Khalil SFH
    IBRO Neurosci Rep; 2021 Dec; 11():103-111. PubMed ID: 34505112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
    Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
    Stahnke AM; Holt KM
    Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
    Zanghì A; Borriello G; Bonavita S; Fantozzi R; Signoriello E; Barone S; Abbadessa G; Cellerino M; Ziccone V; Miele G; Lus G; Valentino P; Bucello S; Inglese M; Centonze D; Avolio C; D'Amico E
    J Neurol; 2024 Jul; 271(7):4495-4502. PubMed ID: 38704488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
    N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.